Cystic Fibrosis (CF) Therapeutics Market

About Cystic Fibrosis Therapeutics Market

Cystic fibrosis therapeutics market is expected to grow with a CAGR of 16.2% during the forecast period of 2018 to 2025. Cystic fibrosis is a chronic, progressive disease causing severe damage to the exocrine glands of body such as pancreas, liver, lungs, and intestines. It is caused by mutation in the gene Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that alters the normal fluid and electrolyte secretion function of the secretory glands. The surging occurrence of cystic fibrosis is the major factor involved in the growth of the cystic fibrosis therapeutics market. Based on the data revealed by the Cystic Fibrosis Research Inc., more than 30,000 people in the United States have cystic fibrosis and approximately 900-1000 new cases of fatal CF arise every year. Various initiatives are being taken by the non-profit organizations and government, which is also contributing towards the market growth of cystic fibrosis therapeutics. The commencement of beneficial programs for patients suffering from cystic fibrosis has stimulated the demand for cystic fibrosis therapeutics.

Market Summary:

The Cystic Fibrosis Therapeutics market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Cystic Fibrosis Therapeutics Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

The study on the worldwide Cystic Fibrosis Therapeutics market strives to offer substantial and profound insights into the current market scenario and the developing growth dynamics. Moreover, the report also provides the market players along with the new contenders a complete view of the market landscape. The inclusive research will enable the well-established as well as the entry-level players to focus on revenue-generating areas of the Cystic Fibrosis Therapeutics market.

Scope and Segmentation of the Report

The segment analysis is one of the significant sections of this report. Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. In the geographical classification, the report highlights the regional markets having high growth potential. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Cystic Fibrosis Therapeutics market.

Competitive Landscape:

The research report also studied the key players operating in the Cystic Fibrosis Therapeutics market. It has evaluated and explained the research & development stages of these companies, their financial performances, and their expansion plans for the coming years. Moreover, the research report also includes the list of planned initiatives that clearly explain the accomplishments of the companies in the recent past.

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products, etc.):

- AbbVie Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
- Alcresta Therapeutics Inc.
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Alexia
Vertex Pharmaceuticals Inc.

Research Methodology

The research methodology of the market is based on both primary as well as secondary research data sources. It compels different factors affecting the Cystic Fibrosis Therapeutics industry such as historical data and market trends, different policies of the government, market environment, market risk factors, market restraints, technological advancements, forthcoming innovations, and obstacles in the industry.

The content of the study subjects includes a total of 8 chapters:

Chapter 1, describe the Cystic Fibrosis Therapeutics market report’s – executive summary, market definition, and market scope. Moreover, the report helps in picking up the crucial information about the said market.

Chapter 2, defines the Research Methodology including primary research, assumptions & exclusions, and secondary data sources. The report follows the simultaneous top-down and bottom approach to provide you the accurate market sizing.

Chapter 3, explains the report segmentation & scope, key market trends (drivers, restraints, and opportunities), along with Porter’s five forces analysis and market share analysis.

Chapter 4: It helps in understanding the key product segments and their future of the Cystic Fibrosis Therapeutics Market. It provides strategic recommendations in key business segments based on the market estimations.

Chapters 5, and 6 to segment the sales by type and application/end-user, with sales market share and growth rate by type, application/end-user, from 2018 to 2016. Our team of Analysts and experts dedicatedly put their effort to provide you the best possible and accurate segmentation data and analysis.

Chapter 7, describes the regional segmentation based on the country level for the forecast period 2018 – 2026. The research report not only provide the market data of the five geographies but also provide the qualitative as well we qualitative information on country level bifurcation.

Chapter 8, to profile the top manufacturers of Cystic Fibrosis Therapeutics, with price, sales, revenue and market share of Cystic Fibrosis Therapeutics in 2016, 2017, and 2018. Players are expected to sign acquisition and collaboration deals to expand their products and services portfolio. Such strategic agreements could help them to improve their client base in other countries and gain a competitive advantage.

Contents:

CHAPTER 1. INTRODUCTION
   ➢ 1.1. RESEARCH METHODOLOGY
      ➢ 1.1.1. ERC desk research
      ➢ 1.1.2. ERC data synthesis
      ➢ 1.1.3. Data validation and market feedback
      ➢ 1.1.4. ERC data sources

CHAPTER 2. CYSTIC FIBROSIS THERAPEUTICS MARKET OVERVIEW
   ➢ 2.1. CYSTIC FIBROSIS THERAPEUTICS MARKET INTRODUCTION
   ➢ 2.2. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE AND GROWTH RATE, 2017-2025
      ➢ 2.2.1. Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Growth Rate (%), (2017-2025)

CHAPTER 3. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY THERAPEUTICS, 2017-2025
   ➢ 3.1. MUCOLYTICS
   ➢ 3.2. BRONCHODILATORS
   ➢ 3.3. CFTR MODULATORS
   ➢ 3.4. PANCREATIC ENZYME SUPPLEMENTS
   ➢ 3.5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY THERAPEUTICS, 2017-2025
      ➢ 3.5.1. Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Therapeutics, 2017-2025
      ➢ 3.5.2. Mucolytics Market Revenue and Growth Rate, 2017-2025
      ➢ 3.5.3. Bronchodilators Market Revenue and Growth Rate, 2017-2025
      ➢ 3.5.4. CFTR modulators Market Revenue and Growth Rate, 2017-2025

CHAPTER 4. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION, 2017-2025
   ➢ 4.1. INHALED DRUGS
   ➢ 4.2. ORAL DRUGS
   ➢ 4.3. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY ROUTE OF ADMINISTRATION, 2017-2025
      ➢ 4.3.1. Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Route of Administration, 2017-2025
      ➢ 4.3.2. Inhaled drugs Market Revenue and Growth Rate, 2017-2025
      ➢ 4.3.3. Oral drugs Market Revenue and Growth Rate, 2017-2025

CHAPTER 5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET BY REGION, 2017-2025
   ➢ 5.1. NORTH AMERICA
      ➢ 5.1.1. U.S.
      ➢ 5.1.2. Canada
      ➢ 5.1.3. Mexico
   ➢ 5.2. EUROPE
      ➢ 5.2.1. U.K.
      ➢ 5.2.2. France
      ➢ 5.2.3. Germany
      ➢ 5.2.4. Italy
      ➢ 5.2.5. Spain
      ➢ 5.2.6. Rest of Europe
   ➢ 5.3. ASIA PACIFIC
      ➢ 5.3.1. China
      ➢ 5.3.2. Japan
      ➢ 5.3.3. India
      ➢ 5.3.4. Korea
      ➢ 5.3.5. Rest of APAC
   ➢ 5.4. SOUTH AMERICA
      ➢ 5.4.1. Brazil
5.4.2. Rest of South America

5.5. REST OF THE WORLD

5.5.1. Middle East

5.5.2. Africa

5.6. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET REVENUE BY REGION, 2017-2025

5.6.1. Global Cystic Fibrosis Therapeutics Market Revenue (Million USD) and Share (%) By Region, 2017-2025

5.6.2. North America Market Revenue and Growth Rate, 2017-2025

5.6.3. Europe Market Revenue and Growth Rate, 2017-2025

5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025

5.6.5. South America Market Revenue and Growth Rate, 2017-2025

5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025

CHAPTER 6. VALUE CHAIN ANALYSIS

CHAPTER 7. MARKET DETERMINANTS

7.1. MARKET DRIVERS

7.2. MARKET RESTRAINTS

7.3. MARKET OPPORTUNITIES

7.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 8. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET COMPETITION BY MANUFACTURERS

8.1. GLOBAL CYSTIC FIBROSIS THERAPEUTICS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)

CHAPTER 9. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MANUFACTURERS ANALYSIS

9.1. ABBVIE INC.

9.1.1. Business Overview

9.1.2. Company Basic Information

9.1.3. Cystic Fibrosis Therapeutics Product Details

9.1.4. AbbVie Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.2. NOVARTIS AG

9.2.1. Business Overview

9.2.2. Company Basic Information

9.2.3. Cystic Fibrosis Therapeutics Product Details

9.2.4. Novartis AG Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.3. TEVA PHARMACEUTICAL INDUSTRIES LTD

9.3.1. Business Overview

9.3.2. Company Basic Information

9.3.3. Cystic Fibrosis Therapeutics Product Details

9.3.4. Teva Pharmaceutical Industries Ltd. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.4. MERCK & CO. INC.

9.4.1. Business Overview

9.4.2. Company Basic Information

9.4.3. Cystic Fibrosis Therapeutics Product Details

9.4.4. Merck & Co. Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.5. ALCRESTA THERAPEUTICS INC.

9.5.1. Business Overview

9.5.2. Company Basic Information

9.5.3. Cystic Fibrosis Therapeutics Product Details

9.5.4. Alcresta Therapeutics Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.6. ALLERGAN PLC

9.6.1. Business Overview

9.6.2. Company Basic Information

9.6.3. Cystic Fibrosis Therapeutics Product Details

9.6.4. Allergan Plc Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.7. F. HOFFMANN-LA ROCHE LTD.

9.7.1. Business Overview

9.7.2. Company Basic Information

9.7.3. Cystic Fibrosis Therapeutics Product Details

9.7.4. F. Hoffmann-La Roche Ltd. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.8. GILEAD SCIENCES, INC.

9.8.1. Business Overview

9.8.2. Company Basic Information

9.8.3. Cystic Fibrosis Therapeutics Product Details

9.8.4. Gilead Sciences, Inc. Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.9. ASTRAZENECA PLC

9.9.1. Business Overview

9.9.2. Company Basic Information

9.9.3. Cystic Fibrosis Therapeutics Product Details

9.9.4. AstraZeneca Plc Cystic Fibrosis Therapeutics Revenue and Gross Margin

9.10. ALAXIA

9.10.1. Business Overview

9.10.2. Company Basic Information

9.10.3. Cystic Fibrosis Therapeutics Product Details